{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:47:41Z","timestamp":1762674461731,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejmech.2020.113094","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T03:37:58Z","timestamp":1607485078000},"page":"113094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton\u2019s tyrosine kinase"],"prefix":"10.1016","volume":"211","author":[{"given":"So\u0148a","family":"Kraj\u010dovi\u010dov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radek","family":"Jorda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-677X","authenticated-orcid":false,"given":"David","family":"Vanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Soural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Kry\u0161tof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113094_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.113094_bib2","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/acs.jmedchem.6b00722","volume":"59","author":"De Lucca","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)","volume":"29","author":"Feng","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2020.113094_bib5","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2020.113094_bib6","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib7","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","article-title":"Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in\u00a0vivo inactivation of Bruton\u2019s tyrosine kinase (BTK)","volume":"62","author":"Watterson","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib8","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in\u00a0vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2020.113094_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040620714539906","article-title":"Bruton\u2019s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib","volume":"5","author":"Aalipour","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2020.113094_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.113094_bib12","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib13","series-title":"Ther. Agents Small Mol. Kinase Inhib","article-title":"Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation","author":"Binnerts","year":"2015"},{"key":"10.1016\/j.ejmech.2020.113094_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/jm500305p","article-title":"Structure-based drug design of RN486, a potent and selective Bruton\u2019s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis","volume":"58","author":"Lou","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14728214.2020.1724282","article-title":"Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib","volume":"25","author":"Molica","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2020.113094_bib16","doi-asserted-by":"crossref","first-page":"112636","DOI":"10.1016\/j.ejmech.2020.112636","article-title":"Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome","volume":"204","author":"Jorda","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejmech.2016.02.018","article-title":"Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors","volume":"112","author":"Sharma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113094_bib18","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.bmcl.2014.02.075","article-title":"Purine derivatives as potent Bruton\u2019s tyrosine kinase (BTK) inhibitors for autoimmune diseases","volume":"24","author":"Shi","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.113094_bib19","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/ol301472a","article-title":"Functionalized orthoesters as powerful building blocks for the efficient preparation of heteroaromatic bicycles","volume":"14","author":"Bastug","year":"2012","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2020.113094_bib20","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1021\/jo00128a024","article-title":"Palladium(0)-Catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters","volume":"60","author":"Ishiyama","year":"1995","journal-title":"J.\u00a0Org. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:17:26Z","timestamp":1759328246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420310667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":20,"alternative-id":["S0223523420310667"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113094","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton\u2019s tyrosine kinase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113094"}}